Zoetis Bought Genomics at 1.8 Times Sales and Merck Paid $647 Million for Hatchery Vision: The Protein Boom's Trade Is Cost Per Pound

The wave is not a pipeline-refill story. TARGAN's WingScan sorts chicks by sex with image recognition at up to 160,000 an hour and sprays respiratory and coccidiosis vaccine to day-old chicks; the genomics business runs DNA testing for livestock and companion animals; AHV International captures herd-level health data on dairy farms. What Merck is buying with $647 million is automation and data capture at the farm, and what Zoetis is buying with $160 million is the genetic layer that decides which animal earns its feed.

Two details sharpen what the deals are worth. Merck recognized a $68 million realized gain on the TARGAN stake it had held since 2017, which means part of the $647 million bought a position it already owned at a marked-up price rather than a new asset. And neither Merck nor TARGAN disclosed revenue, so the price cannot be turned into a multiple; the honest statement is that the market is paying a large, undisclosed sum for poultry automation.

The structure of the deals is telling too. Elanco paid $241 million for AHV International but handed over only $76 million in cash, leaving $97 million deferred and $68 million contingent on performance. Buyers of livestock technology are paying for outcomes rather than for narrative, which is the opposite of how venture capital prices start-ups and a reasonable expectation for businesses whose revenue depends on a producer's cost of production.

Ground beef averaged a record $6.90 a pound in May 2026, roughly 19% above a year earlier, and US farms held 86.2 million head of cattle and calves in January 2026, the smallest count since 1951 and about 9 million below 2019. That is inelastic demand meeting a shrinking herd, and a USDA study puts beef price elasticity at -0.70, so a 10% price rise cuts consumption by about 7%. Rebuilding a herd takes 16 months to two years, and the American Farm Bureau Federation does not expect cattle numbers to expand again until 2028 at the earliest.

The consequence for animal health is counterintuitive. When the scarce asset is the animal, the health budget per head rises while the number of heads falls, and the money goes to whatever protects the pound. Merck's own numbers show it: third-quarter Animal Health sales rose 3.8% to $1,676 million, with US livestock at $199 million and international livestock at $850 million, yet first-nine-month segment sales were flat at $4,849 million. A business that is not adding animals is still adding dollars per animal.

The budget that matters is the producer's. In Illinois beef feeding, feed cost $66.52 per 100 pounds produced in 2025 and accounted for 56% of total costs excluding the feeder animal, against non-feed costs of $51.59. Total cost was $118.11 per 100 pounds, $14.64 above the ten-year average of $103.48, and economic returns still exceeded total costs by $35.98 per 100 pounds. A producer earning roughly $36 of margin on every 100 pounds has budget for precision and little patience for spending that does not show up in feed conversion.

That is the mechanism that makes these deals make sense. A DNA test that identifies the most feed-efficient animal in a herd raises pounds per unit of feed; hatchery vision that replaces manual sexing removes the cost of raising birds the processor cannot sell; on-farm data turns a health event from a herd loss into an early, cheap intervention. None of it needs a new molecule, and none of it registers as an extra dose sold. The value lands in cost per pound, which is the only metric a producer in a shrinking herd is paid on.

Upstream of the farm, the same logic applies to feed and nutrition. ADM processed $84.1 billion of revenue over the trailing twelve months on a 0.41 times sales multiple and 0.1 times net leverage, and Phibro Animal Health grew fiscal first-quarter 2027 revenue 6.3% to $386.8 million at a 33.2% gross margin, with net debt down to 3.0 times EBITDA from 4.7 times a year earlier. Feed tonnage still tracks a herd that cannot grow before 2028, so the upside in these names is per-head nutrition intensity, not more animals.

Record prices at the retail case have not been good news for the companies that process protein. Smithfield Foods posted third-quarter revenue of $3,437 million, down 8.3%, with gross profit falling to $313 million from $479 million a year earlier and net income of $89 million. Tyson Foods saw gross margin compress to 6.6% from 8.2%, with net income of $149 million against $500 million. Meanwhile pork traded at $4.81 a pound against ground beef at $7.95 for the year ending mid-June 2026, so shoppers traded down the case.

The simple conclusion is that the protein boom is a cost-push event downstream and a capital-allocation event upstream. Retailers and processors absorb the higher cost of a scarce animal, while the names selling measurement, genetics and feed conversion collect on the producers' scramble to protect the pound. That is the opposite of the usual protein trade, and it is why the grocery aisle is the wrong place to express this theme.

Zoetis is the cleanest test of whether this wave is priced. Its shares closed at $79.40 on November 6, 2026, down 36.8% over the past year and roughly 40% below the 52-week high of $132.49, and its enterprise value has compressed to 10.6 times trailing EBITDA from 15.5 times at the end of 2025. The reason is companion animal: third-quarter companion animal revenue fell 5% to $1.565 billion, US companion animal fell 8% to $980 million, and management told Reuters it is planning cautiously for 2027 as veterinary costs rise and competition intensifies.

The cash machine kept running while the multiple fell. Over the trailing twelve months to September 30, 2026, Zoetis generated $2.78 billion of operating cash flow and $2.28 billion of free cash flow, repurchased $3.75 billion of stock, paid $886 million of dividends and issued $1.78 billion of net new debt, while spending $169 million on acquisitions. The $160 million genomics purchase is less than 5% of the stock the company bought back over the same window.